Jan 21 (Reuters) - NICOX SA NCOX.PA :
* NICOX FOURTH QUARTER 2019 BUSINESS UPDATE AND FINANCIAL
HIGHLIGHTS
* Q4 2019 NET REVENUE OF EUR 0.6 MILLION
* GROUP HAD CASH AND CASH EQUIVALENTS OF EUR 28.0 MILLION AS
COMPARED WITH EUR 17.4 MILLION AT SEPTEMBER 30, 2019
* NCX 470 PHASE 3 CLINICAL TRIAL PREPARATION: END-OF-PHASE 2
MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA) IS
SCHEDULED IN Q1 2020
* NET REVENUE FOR Q4 OF 2019 WAS EUR 0.6 MILLION, COMPARED
TO EUR
3.3 MILLION FOR Q4 OF 2018
* DECEMBER 31, 2019 CASH POSITION DOES NOT INCLUDE LAST EUR
8
MILLION DRAWN DOWN UNDER BOND FINANCING AGREEMENT WITH KREOS
CAPITAL
Source text for Eikon: ID:nGNX3sKSSc
Further company coverage: NCOX.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48587785110;))